AptarGroup buys up Nanopharm, Gateway Analytical as it looks to broaden reach

BD exiting sterile injectables biz, selling plant and portfolio to Fresenius Kabi
Nanopharm designs and develops oral and nasal pharma products, while Gateway focuses on companies working on injectables. (Getty Images)

Illinois-based AptarGroup is looking to reach out further into biopharma servicing with the acquisitions of Nanopharm and Gateway Analytical.

This will be a change-up for AptarGroup, which currently supplies dispensing, sealing and active packaging for a range of industries including beauty, personal care and home care as well as prescription drugs and injectables.

With the new purchases, which it says are “for a combined enterprise value of approximately $50 million,” it will boost its Aptar Pharma unit’s offerings.

Sponsored by Clinical Ink

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

Nanopharm, which is based in the U.K., works on orally inhaled and nasal drug product design and development services. Gateway Analytical, located in Gibsonia, Pennsylvania, offers detection and predictive analytical services to customers working on injectables.

“The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments,” the company said in a statement.

“We are delighted to welcome the talented teams of Nanopharm and Gateway and their customers to Aptar Pharma,” said Gael Touya, president of Aptar Pharma. “Their expertise and capabilities will deepen our current range of services offered to customers who are developing and testing inhaled and injected medicines. This enables us to participate in a broader spectrum of the pre-clinical, clinical trial and market launch phases of drug development.”

Stephan Tanda, president and CEO of AptarGroup, added: “These strategic investments further strengthen our best in class Pharma business and increase our ability to add to our long-term growth pipeline by adding depth to our service offerings.

“The expertise of two established leaders, Nanopharm, a leader in inhalation and nasal drug development services, and Gateway, a leader in particulate detection and analysis for the injectables market, are complementary to our existing laboratory and analytical services and will bring additional value to our customers as they navigate the challenging regulatory landscape and seek to bring their products to market faster.”

Suggested Articles

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

In a mix-up of trial-based solutions, CRO Parexel is using its recent partnership with Datavant to run a pact with life science data firm TriNetX.

With stints at Genzyme, Bayer and, most recently, TranScrip Partners, Gilbert Wagener, M.D., Ph.D., is now signing up to U.K. biotech Rexgenero.